Please wait while the transcript is being prepared...
0:04
So that completes the first
part of the talk, the introduction.
Now I'm going to go down
into vaccine development efforts
in three main sections.
I'm going to focus initially on
our community vaccine development
goals, I expressed that there
clearly is an unmet medical
need in malaria for a vaccine.
But it's very important that we
target our vaccine development
efforts in an appropriate way
to develop the type of tools
that the community is going to
need to help mitigate the burden
of malaria going forward.
And then I added a few slides
on increasing the probability
of success in reducing risk.
We're in a very resource-constrained
environment in terms
of malaria product development.
These vaccines are intended
for the poorest of the poor.
There's not a high profit
to be made in developing
these types of vaccines.
We're targeting the parasite
here, very difficult to develop
vaccines against parasites.
There are currently no licensed
vaccines against human parasites.
So this is challenging work.
The payoffs are modest.
The risk is high.
So we have to be very prudent
in terms of how we use
the limited resources and make sure
that we're doing everything we can
early in development to
reduce risk and ensure
that we're only investing in
candidates that have the highest
possible probability of success.
And I'm going to touch on that a
little bit in the next few slides.
We have some great tools in malaria
vaccine development that really do
put us at an advantage, and I
think give us a great confidence
that we will be able to
develop highly effective
vaccines over the coming years.
And then to finish, I will
talk about the progress
against these community
goals as things stand today,
with a particular
emphasis on these tools
that we use to make the
most robust decisions
that we can going forward.
